- Home
- AVBP
as 11-22-2024 4:00pm EST
Stocks
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | NEWTOWN SQUARE |
| Market Cap: | 948.5M | IPO Year: | 2024 |
| Target Price: | $36.80 | AVG Volume (30 days): | 146.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.35 - $36.37 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ARRIVENT BIOPHARMA INC News
AVBP Breaking Stock News: Dive into AVBP Ticker-Specific Updates for Smart Investing
MT Newswires
10 days ago
ArriVent BioPharma's Q3 Net Loss Narrows
GlobeNewswire
10 days ago
ArriVent BioPharma Reports Third Quarter 2024 Financial Results
GuruFocus.com
a month ago
Octagon Capital Advisors LP Increases Stake in ArriVent BioPharma Inc
MT Newswires
2 months ago
Oppenheimer Adjusts Price Target on ArriVent BioPharma to $39 From $35, Maintains Outperform Rating
MT Newswires
2 months ago
ArriVent BioPharma Lung Cancer Treatment Study Shows Positive Interim Results
GlobeNewswire
2 months ago
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
Simply Wall St.
3 months ago
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate
Zacks
3 months ago
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet
Compare AVBP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVBP ARRIVENT BIOPHARMA INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.